Ask AI
Expert Viewpoints in MF

CME

Expert Viewpoints in Myelofibrosis: Advancing Treatment Strategies With Next-Generation Therapeutics

Physicians: Maximum of 1.00 AMA PRA Category 1 Credit

Released: February 07, 2024

Expiration: February 06, 2025

Activity

Progress
1
Course Completed

Introduction

In this activity, Abdulraheem Yacoub, MD, reviews key evidence informing optimal treatment of myelofibrosis (MF), with a focus on novel data and emerging strategies.

Please note that the slide thumbnails in this activity link to a PowerPoint slideset. This slideset may be downloaded by clicking on any of the thumbnails within the activity or by clicking here.

Clinical Care Options plans to measure the educational impact of this activity. Some questions will be asked twice: once at the beginning of the activity and once again after the discussion that informs the best choice. Your responses will be aggregated for analysis, and your specific responses will not be shared.

Before continuing with this educational activity, please take a moment to answer the following questions.

If you are a practicing healthcare professional, how many patients with MF do you provide care for in a typical month?

In your current practice, which of the following would you choose as the optimal therapeutic strategy for this patient?

In your current practice, which of the following would you choose as the optimal therapeutic strategy for this patient?

As reported at ASH 2023 for the phase III TRANSFORM-1 trial, each of the following is true regarding treatment with navitoclax plus ruxolitinib vs placebo plus ruxolitinib for patients with JAK inhibitor–naive, higher-risk MF, EXCEPT for which one of the following?